Pfizer (PFE) Tops Q3 EPS by 2c, Lifts FY EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
PFIZER REPORTS THIRD-QUARTER 2017 RESULTS
October 31, 2017 6:45 AM EDTThird-Quarter 2017 Revenues of $13.2 Billion, Reflecting 1% Operational Growth; Unfavorably Impacted by $281 Million, or 2%, Due to the February 2017 Divestiture of Hospira Infusion Systems (HIS) Third-Quarter 2017 Reported Diluted EPS(1) of $0.47, Adjusted Diluted EPS(2) of $0.67 Narrowed Certain 2017 Financial Guidance Ranges; Raised Midpoint of Adjusted Diluted EPS(2) Guidance Range by $0.03 to a Range of $2.58 to $2.62
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2017 and narrowed certain 2017 financial guidance ranges.
Results for the third quarter and first nine months of 2017 and 2016(3) are summarized below.
 OVERALL RESULTS              ($ in millions, exceptper share amounts)
Third-Quarter Nine Months 2017 Â ... More